Clinical Trial Update: A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating furmonertinib in combination as neoadjuvant therapy for resectable EGFR-mutated non-small cell lung cancer; the study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING